Iberdomide – efficacy and safety in RRMM

Safety and efficacy of iberdomide + dexamethasone in patients with triple-class refractory myelomaПодробнее

Results of Iberdomide in Combination with Dex and Daratumumab or Bortezomib in Patients with RRMMПодробнее

Efficacy and Safety of ARI0002H (BCMA-Directed CAR T) in RRMM Patients Presented at EHA 2022Подробнее

Safety and efficacy of elranatamab in RRMM & prior BCMA therapies: Analysis from MagnetisMM studiesПодробнее

The safety and efficacy of iberdomide for the treatment of multiple myelomaПодробнее

Efficacy and safety of KdD in RRMM: Cross‐study comparison of CANDOR and MMY1001Подробнее

The efficacy & role of iberdomide in R/R multiple myelomaПодробнее

Efficacy and safety of elranatamab BCMA-CD3 bispecific antibody, in patients with RRMMПодробнее

Iberdomide in Combination with Dex and Dara, Bort, or Cfz in Pts with RRMMПодробнее

MagnetisMM-30, a Phase 1b Study of ELRA and IBER Combination in Relapsed Refractory Multiple MyelomaПодробнее

Phase Ib/IIa study of iberdomide, in combination with dexamethasone, in patients with RRMMПодробнее

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM...Подробнее

Efficacy and safety of ARI0002H with fractionated initial therapy and booster dose in RRMMПодробнее

First clinical study of iberdomide, a CELMoD, in pts with relapsed/refractory multiple myelomaПодробнее

Update on iberdomide treatment combinations in R/R myelomaПодробнее

Iberdomide with cyclophosphamide and dexamethasone in RRMM: first results from the ICON studyПодробнее

Iberdomide in Combination with DEX in pts with RRMM: Results from the CC-220-MM-001 TrialПодробнее

Efficacy and Safety of Elranatamab in Pts with Relapsed/Refractory Multiple Myeloma: MagnetisMM-3Подробнее

Selinexor for RRMM: Safety and EfficacyПодробнее